News | November 10, 2010

FDA Gives Update on CT Brain Scan Investigation


November 10, 2010 – The U.S. Food and Drug Administration (FDA) has concluded that radiation over-exposure during computed tomography (CT) scans was due to user error, not the scanner manufacturers. The finding comes after the FDA investigated more than 300 reports of over-exposure during brain perfusion scans.

The scanners involved were manufactured by GE Healthcare and Toshiba America Medical Systems. Inspectors found there were no violations of FDA laws and regulations. The FDA evaluated the specifications for multislice CT scanners and found when they were used properly, they did not result in overexposure. The FDA also reviewed literature that supports that the manufacturer-defined protocols do provide reasonable and appropriate image quality and dose. Investigators said there is no evidence the manufacturers were involved in modifying any of the hospitals’ scanning protocols to cause the overexposures.

However, the investigation did reveal improvements the industry could make to improve the safety of their equipment and reduce the likelihood of overexposures.

In 2009, the FDA began investigating complaints about radiation overexposure of 206 patients at the Cedars-Sinai Medical Center. As of Oct. 26, 2010, the agency is aware of approximately 385 patients from six hospitals who were exposed to excess radiation during CT brain perfusion scans.

The FDA said a typical radiation dose of 0.5 Gy is expected for a CT brain perfusion scan.

The American Association of Physicists in Medicine (AAPM) is working with CT manufacturers to specify exam protocols. This includes specialty exams such as brain perfusion studies, which may require relatively higher doses.

The FDA encouraged CT facilities to review their protocols and make sure that the values displayed on the control panel corresponded to the doses normally associated with the protocol.

Additionally, the FDA said that CT operators should be specifically trained on dose-saving features such as automatic exposure control (AEC) before using them. If the user activates AEC without reviewing and adjusting the associated parameters, the default values could lead to an overexposure.

For more information: www.aapm.org/pubs/CTProtocols, www.fda.gov


Related Content

News | Cardiovascular Clinical Studies

May 17, 2024 — Royal Philips, a global leader in health technology, is presenting new retrospective study results ...

Home May 17, 2024
Home
News | Cardiovascular Clinical Studies

May 15, 2024 — A new study demonstrated parity between a minimally invasive procedure to replace the aortic valve in the ...

Home May 15, 2024
Home
News | Cardiovascular Clinical Studies

May 14, 2024 — One of the most common genetic heart diseases worldwide, hypertrophic cardiomyopathy (HCM) causes the ...

Home May 14, 2024
Home
News | Cardiovascular Clinical Studies

May 14, 2024 — An ambitious, nationwide clinical trial led by UVA Health’s Karen Johnston, MD, has provided doctors with ...

Home May 14, 2024
Home
News | Cardiovascular Clinical Studies

May 13, 2024 — Semaglutide reduces the need for loop diuretic use and dose, and has positive effects on symptoms ...

Home May 13, 2024
Home
News | Cardiovascular Clinical Studies

May 13, 2024 — Even though mortality and hospitalization rates have improved, the quality of life for those living with ...

Home May 13, 2024
Home
News | Cardiovascular Clinical Studies

May 10, 2024 — Scientists from Immanuel Kant Baltic Federal University proved that Raman spectroscopy, a method by which ...

Home May 10, 2024
Home
News | Cardiovascular Clinical Studies

May 2, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular ...

Home May 02, 2024
Home
Subscribe Now